Covishield Vaccine Trial
- All
- News
- Videos
-
Biological E Seeks Regulator's Nod For Phase-3 Trial Of Booster Dose
- Tuesday October 12, 2021
- India News | Press Trust of India
Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.
-
www.ndtv.com
-
Vaccination Certificates Via CoWIN For Covishield, Covaxin Trial Participants
- Monday August 23, 2021
- India News | Reported by Parimal Kumar, Edited by Harish Pullanoor
The participants in the clinical trials of Covishield and Covaxin have received their Covid vaccination certificates through the CoWIN app, the Centre has said. Union Health Minister Mansukh Mandaviya thanked their contribution during the pandemic.
-
www.ndtv.com
-
Covaxin's Phase 3 Trial Results Will Be Out In July, Says Bharat Biotech
- Wednesday June 9, 2021
- India News | Reported by Vishnu Som, Edited by Harish Pullanoor
Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today.
-
www.ndtv.com
-
Russian Covid Vaccine Sputnik Could Be Available In India By April: 10 Points
- Thursday February 4, 2021
- India News | Reported by Vishnu Som
Russian-made Coronavirus vaccine Sputnik -- peer-reviewed by the Lancet Medical Journal -- is undergoing trials in India and could be available for use soon. "I believe the vaccine should be available in India from March- April," Deepak Sapra, the chief of API and pharma services at Dr Reddy's Laboratories, which is manufacturing the vaccine, told...
-
www.ndtv.com
-
Give Option To Choose Vaccine: Karnataka Resident Doctors To Centre
- Tuesday January 19, 2021
- India News | Press Trust of India
The president of the Karnataka Association of Resident Doctors, Dr Dayanand Sagar on Tuesday raised concern over the COVID-19 vaccine Covaxin.
-
www.ndtv.com
-
"Will Prefer Covishield Over Covaxin": Delhi Hospital Doctors Concerned
- Sunday January 17, 2021
- India News | Reported by Saurabh Shukla, Sukirti Dwivedi, Edited by Harish Pullanoor
Resident doctors at one of Delhi's biggest healthcare hubs, the Ram Manohar Lohia Hospital, on Saturday demanded they be administered Covishield vaccine and not Covaxin since the former has completed all three stages of trials as required under protocol. The second one, produced by Hyderabad-based Bharat Biotech, is still only undergoing stage-III ...
-
www.ndtv.com
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
- Thursday January 7, 2021
- India News | Edited by Debanish Achom
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
www.ndtv.com
-
Serum Institute's 100-Crore Case After Man Says Vaccine Made Him Ill
- Monday November 30, 2020
- India News | Reported by Vishnu Som, Edited by Chandrashekar Srinivasan
The Serum Institute responded to "malicious and mischievous" allegations by preparing a Rs 100 crore defamation suit against a coronavirus vaccine trial participant who claimed a "virtual neurological breakdown" after being given a dose
-
www.ndtv.com
-
Oxford Vaccine "Could Be Realistic Solution" To Covid: Medical Body ICMR
- Thursday November 12, 2020
- India News | Press Trust of India
The Pune-based Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) on Thursday announced the completion of enrolment of phase-3 clinical trials for potential COVID-19 vaccine Covishield in India.
-
www.ndtv.com
-
"Don't Agree With Rs 80,000 Crore Figure For COVID Vaccine Distribution": Centre
- Wednesday September 30, 2020
- India News | Written by Sukirti Dwivedi
The Union Health Ministry has said it does not agree with the Rs 80,000 crore figure cited by Adar Poonawalla, CEO of Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting trials of Covid vaccine candidates ahead of mass production - for buying and distributing the vaccine in the country. The Mini...
-
www.ndtv.com
-
Biological E Seeks Regulator's Nod For Phase-3 Trial Of Booster Dose
- Tuesday October 12, 2021
- India News | Press Trust of India
Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.
-
www.ndtv.com
-
Vaccination Certificates Via CoWIN For Covishield, Covaxin Trial Participants
- Monday August 23, 2021
- India News | Reported by Parimal Kumar, Edited by Harish Pullanoor
The participants in the clinical trials of Covishield and Covaxin have received their Covid vaccination certificates through the CoWIN app, the Centre has said. Union Health Minister Mansukh Mandaviya thanked their contribution during the pandemic.
-
www.ndtv.com
-
Covaxin's Phase 3 Trial Results Will Be Out In July, Says Bharat Biotech
- Wednesday June 9, 2021
- India News | Reported by Vishnu Som, Edited by Harish Pullanoor
Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today.
-
www.ndtv.com
-
Russian Covid Vaccine Sputnik Could Be Available In India By April: 10 Points
- Thursday February 4, 2021
- India News | Reported by Vishnu Som
Russian-made Coronavirus vaccine Sputnik -- peer-reviewed by the Lancet Medical Journal -- is undergoing trials in India and could be available for use soon. "I believe the vaccine should be available in India from March- April," Deepak Sapra, the chief of API and pharma services at Dr Reddy's Laboratories, which is manufacturing the vaccine, told...
-
www.ndtv.com
-
Give Option To Choose Vaccine: Karnataka Resident Doctors To Centre
- Tuesday January 19, 2021
- India News | Press Trust of India
The president of the Karnataka Association of Resident Doctors, Dr Dayanand Sagar on Tuesday raised concern over the COVID-19 vaccine Covaxin.
-
www.ndtv.com
-
"Will Prefer Covishield Over Covaxin": Delhi Hospital Doctors Concerned
- Sunday January 17, 2021
- India News | Reported by Saurabh Shukla, Sukirti Dwivedi, Edited by Harish Pullanoor
Resident doctors at one of Delhi's biggest healthcare hubs, the Ram Manohar Lohia Hospital, on Saturday demanded they be administered Covishield vaccine and not Covaxin since the former has completed all three stages of trials as required under protocol. The second one, produced by Hyderabad-based Bharat Biotech, is still only undergoing stage-III ...
-
www.ndtv.com
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
- Thursday January 7, 2021
- India News | Edited by Debanish Achom
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
www.ndtv.com
-
Serum Institute's 100-Crore Case After Man Says Vaccine Made Him Ill
- Monday November 30, 2020
- India News | Reported by Vishnu Som, Edited by Chandrashekar Srinivasan
The Serum Institute responded to "malicious and mischievous" allegations by preparing a Rs 100 crore defamation suit against a coronavirus vaccine trial participant who claimed a "virtual neurological breakdown" after being given a dose
-
www.ndtv.com
-
Oxford Vaccine "Could Be Realistic Solution" To Covid: Medical Body ICMR
- Thursday November 12, 2020
- India News | Press Trust of India
The Pune-based Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) on Thursday announced the completion of enrolment of phase-3 clinical trials for potential COVID-19 vaccine Covishield in India.
-
www.ndtv.com
-
"Don't Agree With Rs 80,000 Crore Figure For COVID Vaccine Distribution": Centre
- Wednesday September 30, 2020
- India News | Written by Sukirti Dwivedi
The Union Health Ministry has said it does not agree with the Rs 80,000 crore figure cited by Adar Poonawalla, CEO of Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting trials of Covid vaccine candidates ahead of mass production - for buying and distributing the vaccine in the country. The Mini...
-
www.ndtv.com